26
|
Shrubsole K, Lin TJ, Burton C, Scott J, Finch E. Delivering an iterative Communication Partner Training programme to multidisciplinary healthcare professionals: A pilot implementation study and process evaluation. INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS 2021; 56:620-636. [PMID: 33818902 DOI: 10.1111/1460-6984.12618] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 02/05/2021] [Accepted: 03/11/2021] [Indexed: 06/12/2023]
Abstract
BACKGROUND Despite evidence that Communication Partner Training (CPT) can enable health professionals to communicate more effectively with people with aphasia (PWA), an evidence-practice gap exists. To address this, a tailored implementation intervention was developed and trialled to improve health professionals' implementation of communication strategies in a subacute setting. AIMS To explore the outcomes and perceived feasibility, acceptability and potential effectiveness of an iterative CPT implementation intervention on multidisciplinary healthcare professionals' communication with PWA. METHODS & PROCEDURES The CPT implementation intervention was delivered to two groups of healthcare professionals (n = 6 and 7) approximately 6 months apart. The intervention underwent two iterations targeting emerging barriers to implementation success, with Group 2 receiving a modified version of the Group 1 intervention. A concurrent qualitative process evaluation was conducted to understand key factors determining implementation outcomes. Quantitative outcomes were recorded at baseline and 3-month follow-up, including the Measure of Skill in Supported Communication (MSC), a customized behavioural determinants survey mapped to the Theoretical Domains Framework (TDF) and the Organizational Readiness for Change survey. Focus groups and semi-structured interviews were conducted with health professional participants and the speech-language therapist trainer to explore perceptions of feasibility, acceptability and potential effectiveness. Content analysis was used to analyse the qualitative data, with categories and themes generated. OUTCOMES & RESULTS The Group 2 implementation intervention was adapted based on feedback and reflections from Group 1 participants to incorporate more time for practice interactions and discussion during training, individual follow-up sessions and provision of accessible resources to aid communication attempts. There were greater improvements seen in the Group 2 outcomes on both the MSC and the TDF survey, suggesting that the iterative tailoring of the intervention was successful in addressing the barriers to change and led to improved implementation. The difference between the group's outcomes may also partly be explained by the impact of organizational readiness, which decreased during Group 1's implementation period. Despite similar themes emerging from the stakeholder perspectives in both groups (training factors, implementation facilitators, implementation barriers, and changes in knowledge and practice), these diverted in ways which served to explain the different implementation outcomes. CONCLUSIONS & IMPLICATIONS An iteratively adapted CPT implementation intervention targeting healthcare professionals' use of supported communication strategies was feasible and acceptable for most participants. The implementation intervention was potentially effective in changing participants' communication with PWA, particularly for Group 2. Future CPT implementation efforts should continue to incorporate stakeholder input and tailor strategies to the organizational context, and measure whether outcomes are sustained in the long term. What this paper adds What is already known on the subject CPT is a complex intervention that can improve communication access and outcomes for PWA. However, there are barriers to both delivering CPT programmes to staff, and for staff in modifying their communication behaviours. Despite increasing efforts to improve CPT implementation, it remains largely unclear whether CPT implementation interventions are effective in improving interactions between staff and patients, and what elements of an implementation intervention result in changed behaviour. What this study adds to existing knowledge This study showed that adopting an iterative, barriers-focused approach to implementation facilitated practice change for one of the groups that participated in the programme. Incorporating stakeholder feedback in an ongoing way led to improvements in feasibility, acceptability and potential effectiveness, with several of the main barriers being effectively addressed by the intervention. Some key mechanisms of change were identified. What are the potential or actual clinical implications of this work It is necessary to develop active, targeted implementation strategies to support healthcare professionals to modify their communication, monitor implementation barriers as they arise and modify behaviour-change strategies accordingly. In a similar context, it is suggested that CPT implementation interventions should incorporate the use of audit feedback, physical resources and educational lectures paired with interactions with PWA in order to bring about change, with ongoing support and facilitation.
Collapse
|
27
|
Boyden L, Zhou J, Hu R, Zaki T, Loring E, Scott J, Traupe H, Paller A, Lifton R, Choate K. 180 ASPRV1 mutations cause dominantly inherited ichthyosis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
28
|
Kanwar M, Krainsangka J, Scott J, Barrett T, Everett A, Perer A, Antaki J, Benza R. Hemodynamic Parameters in Predicting Survival in Pulmonary Arterial Hypertension. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
29
|
Gorton HC, Macfarlane H, Edwards R, Farid S, Garner E, Mahroof M, Rasul S, Keating D, Zaman H, Scott J, Maidment I, Strawbridge J. Mental health curricula and Mental Health First Aid in the MPharm. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2021. [DOI: 10.1093/ijpp/riab015.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Introduction
Improving mental health care is an international priority, and one that is championed by the Royal Pharmaceutical Society. (1) In the course of their work, pharmacists frequently encounter people with mental health problems. The extent to which mental health is taught on the undergraduate pharmacy degree in the UK and Ireland, and the inclusion of Mental Health First Aid (MHFA) training, has not be described recently.
Aim
We aimed to determine how mental health teaching is embedded into the MPharm and students’ perception of their own preparedness to help people with their mental health. We explored if and how MHFA training is included, and students’ experience of, or desire to complete this.
Methods
We conducted an anonymous, online questionnaire of UK and Ireland MPharm students, distributed via networks and social media. Students were asked a series of closed questions about mental health teaching in the MPharm, and exposure to MHFA. We analysed answers using descriptive statistics. We included some open-ended questions to enable students to expand on their answers. We used this qualitative data to contextualize findings. We invited one member of staff from each university to answer a modified staff version of the questionnaire, in order to provide a curriculum overview and staff perspective on MHFA provision.
Results
232 students and 13 staff responded, from 22 universities in total. Eighty percent of student participants were female and 70% were in the third or final year of study. Three-quarters of students felt that mental health was not embedded throughout the MPharm. Eighty-percent of students stated that they were taught about neuropharmacology and 44.8% stated that their course included communicating with people about their mental health. One third of students felt that their degree adequately prepared them to help people with their mental health. Twenty-six students (11.6%) had completed MHFA training of which 89% would endorse inclusion of this within the MPharm. Of those who had not completed the training, 81% expressed a desire to do so. Those who completed MHFA training self-reported more preparedness than those who did not, but student numbers were small.
Conclusion
Mental health teaching remains focused on theoretical aspects, such as pharmacology, with less emphasis on practical skills, such as communication skills that might support interactions about mental health. MHFA was viewed by students as one way to enhance this. Of the small number of students who had completed MHFA, they displayed an increased self-reported preparedness. This could, however, be linked to the environmental culture of the programme rather than the training per se. MPharm programmes need sufficient focus on skills including communication and crisis response that may be required by pharmacists, alongside the fundamental scientific knowledge relating to mental health.
References
1. Royal Pharmaceutical Society. No health without mental health: How can pharmacy support people with mental health problems? London: RPS; 2018.
Collapse
|
30
|
Williams M, Jordan A, Scott J, Jones M. Pharmacy professionals’ views regarding the future of NHS patient medicines helpline services: A multimethod qualitative study. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2021. [DOI: 10.1093/ijpp/riab015.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Patient medicines helpline services (PMHS) have been established at some National Health Service (NHS) hospitals in England, to provide medicines-related support to recently discharged hospital patients and carers. However, findings suggest that, due to a lack of resources, considerable variation exists in the operation of PMHS, and that their access, availability, and promotion do not meet national standards regarding helpline provision (1, 2). To develop recommendations for service improvement, this qualitative study sought to examine pharmacy professionals’ views regarding the future of PMHS.
Aim
To examine pharmacy professionals’ perceptions of the future of PMHS, and develop recommendations for service improvement.
Methods
University ethics and Health Research Authority approval were obtained before commencement. Participants comprised pharmacy professionals from acute, mental health, specialist, and community NHS Trusts that provided a PMHS. Invitations to participate in an online qualitative survey and subsequent semi-structured telephone interview were sent via email to pharmacy services at all Trusts that provided a PMHS. Within the survey and the interview schedule was one question “How do you see patient medicines helplines at NHS Trusts developing in the future?” and only the data generated from this open-ended question were analysed for this study. Survey data were collected via SurveyMonkey (n=100). Individuals interested in participating in an interview contacted the research team, resulting in 34 interviews. Interviews were conducted from May-October 2018, and ranged from 16 to 53 minutes. Braun and Clarke’s inductive reflexive thematic analysis was used to analyse the data. Guidelines for enhancing the validity and trustworthiness of qualitative research were used.
Results
Two themes were generated from the survey and interviews. Enhancing value for service users identifies suggestions for improving the value of PMHS for service users. These include providing access methods beyond the telephone, and providing patients/carers with post-discharge follow-up calls from a pharmacist. Improving efficiency identifies that, in the future, and in line with NHS plans for efficiency and shared resources, PMHS may become centralised or provided by community pharmacies. Centralised services were considered to likely have more resources available to provide a patient medicines information service compared to hospital pharmacies. Participants often referred to the Carter report and sustainability and transformation plans, which promote the sharing of resources within regions. However, such a change was perceived to only increase efficiency if patient information can be shared between relevant healthcare settings.
Conclusion
PMHS are perceived by pharmacy professionals as likely to become centralised in the future (i.e., provided regionally or nationally) or provided by community pharmacies. This is dependent upon patients’ information being shared between hospitals and the centralised PMHS or pharmacies. To enhance the value of PMHS for service users, providers could establish other methods of access, such as email and video consultation. A limitation of this study is that it did not seek the perspectives of pharmacy professionals who do not provide a PMHS, other healthcare professionals, nor patients and carers. Considering the uncertainty around the future of PMHS, research should establish the best way to support all patients and carers regarding medicines following hospital discharge.
References
1. Williams MJ, Jones MD, Jordan AL, Scott JA. Operating a patient medicines helpline. A survey study exploring current practice in England using the RE-AIM evaluation framework. BMC Health Serv Res. 2018; doi:10.1186/s12913-018-3690-9
2. Williams M, Jordan A, Scott J, Jones MD. Pharmacy professionals’ experiences and perceptions of providing NHS patient medicines helpline services: a qualitative study. BMC Health Serv Res. 2020; doi.org/10.1186/s12913-020-05182-w.
Collapse
|
31
|
Thamboo A, Kilty S, Witterick I, Chan Y, Chin CJ, Janjua A, Javer A, Lee J, Monterio E, Rotenberg B, Scott J, Smith K, Sommer DD, Sowerby L, Tewfik M, Wright E, Desrosiers M. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg 2021; 50:15. [PMID: 33750471 PMCID: PMC7945300 DOI: 10.1186/s40463-021-00493-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 01/11/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Recent evidence suggests that biologic therapy with targeted activity within the Type 2 inflammatory pathway can improve the clinical signs and symptoms of chronic rhinosinusitis with nasal polyposis (CRSwNP). There remains a population in CRSwNP that despite medical therapy and endoscopic sinus surgery have persistent signs and symptoms of disease. Therefore, biologics, monoclonal antibody agents, could be beneficial therapeutic treatments for these patients. There have been eight randomized, double-blind, placebo-controlled trails performed for CRSwNP targeted components of the Type 2 inflammatory pathway, notably interleukin (IL)-4, IL-5 and IL-13, IL-5R, IL-33, and immunoglobulin (Ig)E. However, there are no formal recommendations for the optimal use of biologics in managing Chronic Rhinosinusitis (CRS) within the Canadian health care environment. METHODS A Delphi Method process was utilized involving three rounds of questionnaires in which the first two were completed individually online and the third was discussed on a virtual platform with all the panelists. 17 fellowship trained rhinologists across Canada evaluated the 28 original statements on a scale of 1-10 and provided comments. A rating within 1-3 indicated disagreement, 8-10 demonstrated agreement and 4-7 represented being neutral towards a statement. All ratings were quantitively reviewed by mean, median, mode, range and standard deviation. Consensus was defined by removing the highest and lowest of the scores and using the "3 point relaxed system". RESULTS After three rounds, a total of 11 statements achieved consensus. This white paper only contains the final agreed upon statements and clear rationale and support for the statements regarding the use of biologics in patients with CRS. CONCLUSION This white paper provides guidance to Canadian physicians on the use of biologic therapy for the management of patients with CRS, but the medical and surgical regimen should ultimately be individualized to the patient. As more biologics become available and additional trials are published we will provide updated versions of this white paper every few years.
Collapse
|
32
|
Wlodek E, Kirkpatrick RB, Andrews S, Noble R, Schroyer R, Scott J, Watson CJE, Clatworthy M, Harrison EM, Wigmore SJ, Stevenson K, Kingsmore D, Sheerin NS, Bestard O, Stirnadel-Farrant HA, Abberley L, Busz M, DeWall S, Birchler M, Krull D, Thorneloe KS, Weber A, Devey L. A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PLoS One 2021; 16:e0247972. [PMID: 33684160 PMCID: PMC7939287 DOI: 10.1371/journal.pone.0247972] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Accepted: 12/11/2020] [Indexed: 01/08/2023] Open
Abstract
INTRODUCTION Delayed graft function (DGF) following renal transplantation is a manifestation of acute kidney injury (AKI) leading to poor long-term outcome. Current treatments have limited effectiveness in preventing DGF. Interleukin-18 (IL18), a biomarker of AKI, induces interferon-γ expression and immune activation. GSK1070806, an anti-IL18 monoclonal antibody, neutralizes activated (mature) IL18 released from damaged cells following inflammasome activation. This phase IIa, single-arm trial assessed the effect of a single dose of GSK1070806 on DGF occurrence post donation after circulatory death (DCD) kidney transplantation. METHODS The 3 mg/kg intravenous dose was selected based on prior studies and physiologically based pharmacokinetic (PBPK) modeling, indicating the high likelihood of a rapid and high level of IL18 target engagement when administered prior to kidney allograft reperfusion. Utilization of a Bayesian sequential design with a background standard-of-care DGF rate of 50% based on literature, and confirmed via extensive registry data analyses, enabled a statistical efficacy assessment with a minimal sample size. The primary endpoint was DGF frequency, defined as dialysis requirement ≤7 days post transplantation (except for hyperkalemia). Secondary endpoints included safety, pharmacokinetics and pharmacodynamic biomarkers. RESULTS GSK1070806 administration was associated with IL18-GSK1070806 complex detection and increased total serum IL18 levels due to IL18 half-life prolongation induced by GSK1070806 binding. Interferon-γ-induced chemokine levels declined or remained unchanged in most patients. Although the study was concluded prior to the Bayesian-defined stopping point, 4/7 enrolled patients (57%) had DGF, exceeding the 50% standard-of-care rate, and an additional two patients, although not reaching the protocol-defined DGF definition, demonstrated poor graft function. Six of seven patients experienced serious adverse events (SAEs), including two treatment-related SAEs. CONCLUSION Overall, using a Bayesian design and extensive PBPK dose modeling with only a small sample size, it was deemed unlikely that GSK1070806 would be efficacious in preventing DGF in the enrolled DCD transplant population. TRIAL REGISTRATION NCT02723786.
Collapse
|
33
|
Metrebian N, Carr E, Goldsmith K, Weaver T, Pilling S, Shearer J, Woolston-Thomas K, Tas B, Cooper C, Getty CA, van der Waal R, Kelleher M, Finch E, Bijral P, Taylor D, Scott J, Strang J. Mobile telephone delivered contingency management for encouraging adherence to supervised methadone consumption: feasibility study for an RCT of clinical and cost-effectiveness (TIES). Pilot Feasibility Stud 2021; 7:14. [PMID: 33407950 PMCID: PMC7789356 DOI: 10.1186/s40814-020-00761-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 12/18/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Prescription methadone or buprenorphine enables people with opioid use disorder to stop heroin use safely while avoiding withdrawal. To ensure methadone is taken as prescribed and to prevent diversion onto the illicit market, people starting methadone take their daily dose under a pharmacist's supervision. Many patients miss their daily methadone dose risking withdrawal, craving for heroin and overdose due to loss of heroin tolerance. Contingency management (CM) can improve medication adherence, but remote delivery using technology may be resource-light and cost-effective. We developed an innovative way to deliver CM by mobile telephone. Software monitors patients' attendance and supervised methadone consumption through an internet self-login at the pharmacy and sends reinforcing text messages to patients' mobile telephones. A linked system sends medication adherence reports to prescribers and provides early warning alerts of missed doses. A pre-paid debit card system provides financial incentives. METHODS A cluster randomised controlled trial design was used to test the feasibility of conducting a future trial of mobile telephone CM to encourage adherence to supervised methadone in community pharmacies. Each cluster (drug service/3 allied pharmacies) was randomly allocated to provide patient's presenting for a new episode of opiate agonist treatment (OAT) with either (a) mobile telephone text message CM, (b) mobile telephone text message reminders, or (c) no text messages. We assessed acceptability of the interventions, recruitment, and follow-up procedures. RESULTS Four drug clinics were approached and three recruited. Thirty-three pharmacists were approached and 9 recruited. Over 3 months, 173 individuals were screened and 10 enrolled. Few patients presented for OAT and high numbers were excluded due to receiving buprenorphine or not attending participating pharmacies. There was 96% consistency in recording medication adherence by self-login vs. pharmacy records. In focus groups, CM participants were positive about using self-login, the text messages, and debit card. Prescribers found weekly reporting, time saving, and allowed closer monitoring of patients. Pharmacists reported that the tablet device was easy to host. CONCLUSION Mobile telephone CM worked well, but a planned future trial will use modified eligibility criteria (existing OAT patients who regularly miss their methadone/buprenorphine doses) and increase the number of participating pharmacies. TRIAL REGISTRATION The trial is retrospectively registered, ISRCTN 58958179 .
Collapse
|
34
|
Arnab P, Croxford R, Scott J, Wiesner L, Cohen K, Wasserman S. Clinical phenotype and risk factors for severe efavirenz-associated neurotoxicity amongst inpatients in Cape Town, South Africa. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
35
|
Lindsay K, Caplan N, Weber T, Salomoni S, De Martino E, Winnard A, Scott J, Young E, Hides J, Hodges PW, Debuse D. Effects of a six-week exercise intervention on function, pain and lumbar multifidus muscle cross-sectional area in chronic low back pain: A proof-of-concept study. Musculoskelet Sci Pract 2020; 49:102190. [PMID: 32861357 DOI: 10.1016/j.msksp.2020.102190] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 05/08/2020] [Accepted: 05/11/2020] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Exercise with the Functional Re-adaptive Exercise Device (FRED) has previously been shown to activate the lumbar multifidus (LM) and transversus abdominis (TrA) muscles in non-symptomatic volunteers. This study aimed to determine the effects of a six-week FRED exercise intervention on pain intensity, patient-reported function and LM cross sectional area (CSA) in people with chronic non-specific low back pain (LBP). METHODS Thirteen participants undertook six weeks of FRED exercise for up to 15 min, three times per week. At six weeks pre-, immediately pre-, immediately post-, and six and 15 weeks post-intervention, participants completed the Numeric Pain Rating Scale, Patient-Specific Functional Scale, and ultrasound imaging was used to assess the size of the LM muscles at L5 level. Changes in outcomes were assessed using effect size, confidence intervals and minimum clinically important difference (MCID). RESULTS There was no improvement in pain intensity following the intervention. Patient-reported function improved by at least twice the MCID for all follow-up assessments compared to immediately pre-intervention (d = 4.20-6.58). Lumbar multifidus CSA showed a large effect size increase from immediately pre-intervention to immediately post-intervention (d = 0.8-1.1); this was maintained at six weeks post-intervention (not measured at 15 weeks post-intervention). CONCLUSION Six weeks of FRED exercise improved physical function in all 13 participants with chronic non-specific LBP who took part in this study and most participants' lumbar multifidus muscle CSA. On this basis, it may be an effective intervention for people with chronic LBP and should now be tested in a randomised controlled trial.
Collapse
|
36
|
Amuluru K, Sahlein D, Al-Mufti F, Payner T, Kulwin C, DeNardo A, Scott J. The Dilator-Dotter Technique: A Modified Method of Rapid Internal Carotid Artery Revascularization in Acute Ischemic Stroke. AJNR Am J Neuroradiol 2020; 41:1863-1868. [PMID: 32883663 DOI: 10.3174/ajnr.a6733] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 06/15/2020] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Acute ischemic stroke due to tandem occlusive lesions involves high-grade ICA stenosis or occlusion with a distal intracranial occlusion. Several approaches and devices exist in the treatment of tandem occlusions; however, a consensus on the optimal technique does not exist. The Dotter technique is a method of catheter-based angioplasty to recanalize cervical ICA occlusions. We present a modified dilator-Dotter technique, which involves a polyethylene, tapered inner dilator to initially cross the occlusion, followed by guide catheterization and subsequent intracranial thrombectomy. The purpose of this study was to examine the safety and efficacy of this dilator-Dotter technique. MATERIALS AND METHODS We performed a retrospective review of patients with acute stroke due to tandem ICA intracranial occlusions, treated with our dilator-Dotter technique and thrombectomy between June 2018 and December 2019. We examined clinical, radiographic, and procedural data, as well as complications and outcomes. RESULTS Thirty-two patients were included. In 100% of cases, the dilator-Dotter technique resulted in ICA recanalization allowing successful thrombectomy. TICI 2b-3 revascularization was obtained in 31 patients (96%), within an average time of 25 minutes. The average preprocedural ICA stenosis was 98%, including 23 patients (72%) with complete occlusion. Following the dilator-Dotter technique, average ICA stenosis improved to 59%. There were no instances of death, iatrogenic dissection, emboli to new territory, or symptomatic intracranial hemorrhage. CONCLUSIONS The dilator-Dotter technique may be a safe and effective modification of the traditional Dotter technique in allowing rapid ICA recanalization in cases of acute ischemic stroke due to tandem occlusions.
Collapse
|
37
|
Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aich A, Aiello L, Ain A, Ajith P, Akcay S, Allen G, Allocca A, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Ansoldi S, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Asali Y, Ascenzi S, Ashton G, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baer AM, Baird J, Baldaccini F, Ballardin G, Ballmer SW, Bals A, Balsamo A, Baltus G, Banagiri S, Bankar D, Bankar RS, Barayoga JC, Barbieri C, Barish BC, Barker D, Barkett K, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Benjamin MG, Bentley JD, Bergamin F, Berger BK, Bergmann G, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bhandari AV, Bidler J, Biggs E, Bilenko IA, Billingsley G, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Bissenbayeva G, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bobba F, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose S, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Breschi M, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Bruno G, Bruntz R, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buscicchio R, Buskulic D, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callaghan JD, Callister TA, Calloni E, Camp JB, Canepa M, Cannon KC, Cao H, Cao J, Carapella G, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Castañeda J, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi O, Chakravarti K, Chan C, Chan M, Chandra K, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Chen HY, Chen X, Chen Y, Cheng HP, Cheong CK, Chia HY, Chiadini F, Chierici R, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu Q, Chua S, Chung KW, Chung S, Ciani G, Ciecielag P, Cieślar M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Clesse S, Cleva F, Coccia E, Cohadon PF, Cohen D, Colleoni M, Collette CG, Collins C, Colpi M, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cudell JR, Cullen TJ, Cumming A, Cummings R, Cunningham L, Cuoco E, Curylo M, Canton TD, Dálya G, Dana A, Daneshgaran-Bajastani LM, D'Angelo B, Danilishin SL, D'Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier LEH, Dattilo V, Dave I, Davier M, Davies GS, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Delfavero M, De Lillo N, Del Pozzo W, DeMarchi LM, D'Emilio V, Demos N, Dent T, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Diaz-Ortiz M, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla AK, Dmitriev A, Doctor Z, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Durante O, D'Urso D, Dwyer SE, Easter PJ, Eddolls G, Edelman B, Edo TB, Edy O, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Ejlli A, Errico L, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Ewing BE, Fafone V, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Feicht J, Fejer MM, Feng F, Fenyvesi E, Ferguson DL, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fittipaldi R, Fitz-Axen M, Fiumara V, Flaminio R, Floden E, Flynn E, Fong H, Font JA, Forsyth PWF, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fronzè G, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Galaudage S, Ganapathy D, Ganguly A, Gaonkar SG, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Gibson DR, Gier C, Gill K, Glanzer J, Gniesmer J, Godwin P, Goetz E, Goetz R, Gohlke N, Goncharov B, González G, Gopakumar A, Gossan SE, Gosselin M, Gouaty R, Grace B, Grado A, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson EM, Griggs HL, Grignani G, Grimaldi A, Grimm SJ, Grote H, Grunewald S, Gruning P, Guidi GM, Guimaraes AR, Guixé G, Gulati HK, Guo Y, Gupta A, Gupta A, Gupta P, Gustafson EK, Gustafson R, Haegel L, Halim O, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hansen TJ, Hanson J, Harder T, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hasskew RK, Haster CJ, Haughian K, Hayes FJ, Healy J, Heidmann A, Heintze MC, Heinze J, Heitmann H, Hellman F, Hello P, Hemming G, Hendry M, Heng IS, Hennes E, Hennig J, Heurs M, Hild S, Hinderer T, Hoback SY, Hochheim S, Hofgard E, Hofman D, Holgado AM, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Howell EJ, Hoy CG, Huang Y, Hübner MT, Huerta EA, Huet D, Hughey B, Hui V, Husa S, Huttner SH, Huxford R, Huynh-Dinh T, Idzkowski B, Iess A, Inchauspe H, Ingram C, Intini G, Isac JM, Isi M, Iyer BR, Jacqmin T, Jadhav SJ, Jadhav SP, James AL, Jani K, Janthalur NN, Jaranowski P, Jariwala D, Jaume R, Jenkins AC, Jiang J, Johns GR, Johnson-McDaniel NK, Jones AW, Jones DI, Jones JD, Jones P, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Kashyap R, Kasprzack M, Kastaun W, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Keivani A, Kennedy R, Key JS, Khadka S, Khalili FY, Khan I, Khan S, Khan ZA, Khazanov EA, Khetan N, Khursheed M, Kijbunchoo N, Kim C, Kim GJ, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimball C, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Knyazev E, Koch P, Koehlenbeck SM, Koekoek G, Koley S, Kondrashov V, Kontos A, Koper N, Korobko M, Korth WZ, Kovalam M, Kozak DB, Kringel V, Krishnendu NV, Królak A, Krupinski N, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar R, Kumar S, Kuo L, Kutynia A, Lackey BD, Laghi D, Lalande E, Lam TL, Lamberts A, Landry M, Lane BB, Lang RN, Lange J, Lantz B, Lanza RK, La Rosa I, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee CH, Lee HM, Lee HW, Lee J, Lee K, Lehmann J, Leroy N, Letendre N, Levin Y, Li AKY, Li J, Li K, Li TGF, Li X, Linde F, Linker SD, Linley JN, Littenberg TB, Liu J, Liu X, Llorens-Monteagudo M, Lo RKL, Lockwood A, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod DM, MacMillan IAO, Macquet A, Magaña Hernandez I, Magaña-Sandoval F, Magee RM, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Mapelli M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martinez V, Martynov DV, Masalehdan H, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Mavalvala N, Maynard E, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIsaac C, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Mehta AK, Mejuto Villa E, Melatos A, Mendell G, Mercer RA, Mereni L, Merfeld K, Merilh EL, Merritt JD, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Meylahn F, Mhaske A, Miani A, Miao H, Michaloliakos I, Michel C, Middleton H, Milano L, Miller AL, Millhouse M, Mills JC, Milotti E, Milovich-Goff MC, Minazzoli O, Minenkov Y, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Mo G, Mogushi K, Mohapatra SRP, Mohite SR, Molina-Ruiz M, Mondin M, Montani M, Moore CJ, Moraru D, Morawski F, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mozzon S, Muciaccia F, Mukherjee A, Mukherjee D, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Murray PG, Nagar A, Nardecchia I, Naticchioni L, Nayak RK, Neil BF, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Ng KY, Ng S, Nguyen C, Nguyen P, Nichols D, Nichols SA, Nissanke S, Nitz A, Nocera F, Noh M, North C, Nothard D, Nuttall LK, Oberling J, O'Brien BD, Oganesyan G, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Olivetto C, Oppermann P, Oram RJ, O'Reilly B, Ormiston RG, Ortega LF, O'Shaughnessy R, Ossokine S, Osthelder C, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page MA, Pagliaroli G, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pan H, Panda PK, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Payne E, Pearlstone BL, Pechsiri TC, Pedersen AJ, Pedraza M, Pele A, Penn S, Perego A, Perez CJ, Périgois C, Perreca A, Perriès S, Petermann J, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piendibene M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Piotrzkowski K, Pirello M, Pitkin M, Plastino W, Poggiani R, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Powell J, Prajapati AK, Prasai K, Prasanna R, Pratten G, Prestegard T, Principe M, Prodi GA, Prokhorov L, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez PJ, Raab FJ, Raaijmakers G, Radkins H, Radulesco N, Raffai P, Rafferty H, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Rettegno P, Ricci F, Richardson CJ, Richardson JW, Ricker PM, Riemenschneider G, Riles K, Rizzo M, Robertson NA, Robinet F, Rocchi A, Rodriguez-Soto RD, Rolland L, Rollins JG, Roma VJ, Romanelli M, Romano R, Romel CL, Romero-Shaw IM, Romie JH, Rose CA, Rose D, Rose K, Rosińska D, Rosofsky SG, Ross MP, Rowan S, Rowlinson SJ, Roy PK, Roy S, Roy S, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salafia OS, Salconi L, Saleem M, Salemi F, Samajdar A, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sanders JR, Santiago KA, Santos E, Sarin N, Sassolas B, Sathyaprakash BS, Sauter O, Savage RL, Savant V, Sawant D, Sayah S, Schaetzl D, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schulte BW, Schutz BF, Schwarm O, Schwartz E, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Sharifi S, Shahriar MS, Sharma A, Sharma P, Shawhan P, Shen H, Shikauchi M, Shink R, Shoemaker DH, Shoemaker DM, Shukla K, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Singer LP, Singh D, Singh N, Singha A, Singhal A, Sintes AM, Sipala V, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smetana J, Smith JR, Smith RJE, Somala S, Son EJ, Soni S, Sorazu B, Sordini V, Sorrentino F, Souradeep T, Sowell E, Spencer AP, Spera M, Srivastava AK, Srivastava V, Staats K, Stachie C, Standke M, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson S, Stocks D, Stops DJ, Stover M, Strain KA, Stratta G, Strunk A, Sturani R, Stuver AL, Sudhagar S, Sudhir V, Summerscales TZ, Sun L, Sunil S, Sur A, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Tanasijczuk AJ, Tanner DB, Tao D, Tápai M, Tapia A, Tapia San Martin EN, Tasson JD, Taylor R, Tenorio R, Terkowski L, Thirugnanasambandam MP, Thomas M, Thomas P, Thompson JE, Thondapu SR, Thorne KA, Thrane E, Tinsman CL, Saravanan TR, Tiwari S, Tiwari S, Tiwari V, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Tosta E Melo I, Töyrä D, Travasso F, Traylor G, Tringali MC, Tripathee A, Trovato A, Trudeau RJ, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tsutsui T, Turconi M, Ubhi AS, Udall R, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Utina AC, Vahlbruch H, Vajente G, Valdes G, Valentini M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, Van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Veske D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vivanco FH, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace GS, Wallace L, Walsh S, Wang JZ, Wang S, Wang WH, Ward RL, Warden ZA, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Weßels P, Westhouse JW, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken DM, Williams D, Willis JL, Willke B, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong ICF, Wright JL, Wu DS, Wysocki DM, Xiao L, Yamamoto H, Yang L, Yang Y, Yang Z, Yap MJ, Yazback M, Yeeles DW, Yu H, Yu H, Yuen SHR, Zadrożny AK, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhao G, Zhou M, Zhou Z, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW190521: A Binary Black Hole Merger with a Total Mass of 150 M_{⊙}. PHYSICAL REVIEW LETTERS 2020; 125:101102. [PMID: 32955328 DOI: 10.1103/physrevlett.125.101102] [Citation(s) in RCA: 73] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 06/19/2020] [Accepted: 07/09/2020] [Indexed: 06/08/2023]
Abstract
On May 21, 2019 at 03:02:29 UTC Advanced LIGO and Advanced Virgo observed a short duration gravitational-wave signal, GW190521, with a three-detector network signal-to-noise ratio of 14.7, and an estimated false-alarm rate of 1 in 4900 yr using a search sensitive to generic transients. If GW190521 is from a quasicircular binary inspiral, then the detected signal is consistent with the merger of two black holes with masses of 85_{-14}^{+21} M_{⊙} and 66_{-18}^{+17} M_{⊙} (90% credible intervals). We infer that the primary black hole mass lies within the gap produced by (pulsational) pair-instability supernova processes, with only a 0.32% probability of being below 65 M_{⊙}. We calculate the mass of the remnant to be 142_{-16}^{+28} M_{⊙}, which can be considered an intermediate mass black hole (IMBH). The luminosity distance of the source is 5.3_{-2.6}^{+2.4} Gpc, corresponding to a redshift of 0.82_{-0.34}^{+0.28}. The inferred rate of mergers similar to GW190521 is 0.13_{-0.11}^{+0.30} Gpc^{-3} yr^{-1}.
Collapse
|
38
|
Tasdemir N, Savariau L, Scott J, Latoche JD, Hou W, Biery K, Chung M, Bossart EA, Sreekumar S, Brown DD, Nasrazadani A, Qin Y, Hooda J, Chen F, Castro CA, Anderson CJ, Atkinson J, Lucas PC, Davison NE, Lee AV, Oesterreich S. Abstract LB-002: ER alpha-positive human cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-lb-002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Invasive lobular breast carcinoma (ILC) is the most common special histological subtype of breast cancer, accounting for 10-15% of all cases, and characterized by the loss of adherens junctions through inactivating mutations in E-cadherin. Although currently existing genetically engineered mouse models of ILC faithfully capture its dyscohesive, single-file growth and expression of estrogen receptor alpha (ER), they do not fully recapitulate all aspects of human ILC such as unique sites of metastases and endocrine response. While recent work on human ILC cell lines has proven them useful for studying ILC in vitro, there is limited data on their growth as xenografts in mice and their fidelity as in vivo models. Using dual bioluminescent and fluorescent labeled ER-positive human ILC cell lines (MDA-MB-134, SUM44PE, MDA-MB-330, BCK4), herein we characterized their growth orthotopically and at secondary sites following spontaneous or experimental metastasis. Mammary fat pad xenografts gave rise to primary tumors with single-file infiltration and cytoplasmic translocation of p120-catenin, characteristic of human ILC. The tumor microenvironment exhibited deposition of collagen fibers and infiltration by fibroblasts and neutrophils. In this orthotopic model, we observed spontaneous metastases of most cell lines to bones, brain and ovaries, closely mirroring the clinical patterns of human ILC dissemination. In contrast, experimental metastases were only observed following intravenous or intracardiac xenografts of MDA-MB-134 cells. Interestingly, tail vein injections of this cell line lead to colonization of bones and lymph nodes but not of lungs, while intracardiac injections resulted in brain, bone and lymph node metastases. Importantly, we observed high ER expression in the primary tumors and the metastatic lesions, along with a significant response to the selective ER down-regulator fulvestrant in both the mammary fat pad and intracardiac models. Ongoing work focused on genomic and transcriptional analyses of primary tumors and metastases, as well as of cell lines isolated from these lesions, will reveal additional mechanistic insights into the biology of ILC dissemination. This is the first report of ER-positive and endocrine responsive human cell line xenografts faithfully representing unique ILC features such as ovarian metastases. These versatile models will serve as an invaluable pre-clinical platform for validating candidate ILC genetic drivers and testing novel therapeutics towards translation into the clinic.
Citation Format: Nilgun Tasdemir, Laura Savariau, Julie Scott, Joseph D. Latoche, Weizhou Hou, Kyle Biery, Minji Chung, Emily A. Bossart, Sreeja Sreekumar, Daniel D. Brown, Azadeh Nasrazadani, Ye Qin, Jagmohan Hooda, Fangyuan Chen, Carlos A. Castro, Carolyn J. Anderson, Jennifer Atkinson, Peter C. Lucas, Nancy E. Davison, Adrian V. Lee, Steffi Oesterreich. ER alpha-positive human cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-002.
Collapse
|
39
|
Tripathi R, Mazmudar R, Bordeaux J, Scott J. LB930 Leaving against medical advice among patients hospitalized for dermatologic conditions. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.05.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
40
|
Scott J, Bellivier F, Manchia M, Schulze T, Alda M, Etain B, Garnham J, Nunes A, O'Donovan C, Slaney C, Bauer M, Pfennig A, Reif A, Kittel‐Schneider S, Veeh J, Zompo MD, Ardau R, Chillotti C, Severino G, Kato T, Ozaki N, Kusumi I, Hashimoto R, Akiyama K, Kelso J. Can network analysis shed light on predictors of lithium response in bipolar I disorder? Acta Psychiatr Scand 2020; 141:522-533. [PMID: 32068882 DOI: 10.1111/acps.13163] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 02/10/2020] [Accepted: 02/16/2020] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To undertake a large-scale clinical study of predictors of lithium (Li) response in bipolar I disorder (BD-I) and apply contemporary multivariate approaches to account for inter-relationships between putative predictors. METHODS We used network analysis to estimate the number and strength of connections between potential predictors of good Li response (measured by a new scoring algorithm for the Retrospective Assessment of Response to Lithium Scale) in 900 individuals with BD-I recruited to the Consortium of Lithium Genetics. RESULTS After accounting for co-associations between potential predictors, the most important factors associated with the good Li response phenotype were panic disorder, manic predominant polarity, manic first episode, age at onset between 15-32 years and family history of BD. Factors most strongly linked to poor outcome were comorbid obsessive-compulsive disorder, alcohol and/or substance misuse, and/or psychosis (symptoms or syndromes). CONCLUSIONS Network analysis can offer important additional insights to prospective studies of predictors of Li treatment outcomes. It appears to especially help in further clarifying the role of family history of BD (i.e. its direct and indirect associations) and highlighting the positive and negative associations of different subtypes of anxiety disorders with Li response, particularly the little-known negative association between Li response and obsessive-compulsive disorder.
Collapse
|
41
|
Jordan LC, Cook TM, Cook S, Dalton SJ, Collins K, Scott J, Peden CJ. Sustaining better care for patients undergoing emergency laparotomy. Anaesthesia 2020; 75:1321-1330. [DOI: 10.1111/anae.15088] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2020] [Indexed: 12/20/2022]
|
42
|
McGowan CR, Wright T, Nitsch D, Lewer D, Brathwaite R, Scott J, Hope V, Ciccarone D, Dunn J, Gillmore J, Story A, Harris M. High prevalence of albuminuria amongst people who inject drugs: A cross-sectional study. Sci Rep 2020; 10:7059. [PMID: 32341462 PMCID: PMC7184598 DOI: 10.1038/s41598-020-63748-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 03/30/2020] [Indexed: 01/24/2023] Open
Abstract
Albuminuria is a key biomarker for cardiovascular disease and chronic kidney disease. Our study aimed to describe the prevalence of albuminuria amongst people who inject drugs in London and to test any potential associations with demographic characteristics, past diagnoses, and drug preparation and administration practices. We carried out a cross-sectional survey amongst people who use drugs in London. The main outcome measure was any albuminuria including both microalbuminuria and macroalbuminuria. Three-hundred and sixteen samples were tested by local laboratory services. Our study initially employed point-of-care testing methods but this resulted in a high number of false positives. Our findings suggest the prevalence of albuminuria amongst PWID is twice that of the general population at 19% (95%CI 15.3–24.0%). Risk factors associated with albuminuria were HIV (aOR 4.11 [95% CI 1.37–12.38]); followed by overuse of acidifier for dissolving brown heroin prior to injection (aOR 2.10 [95% CI 1.04–4.22]). Albuminuria is high amongst people who inject drugs compared to the general population suggesting the presence of increased cardiovascular and renal pathologies. This is the first study to demonstrate an association with acidifier overuse. Dehydration may be common amongst this population and may affect the diagnostic accuracy of point-of-care testing for albuminuria.
Collapse
|
43
|
Lewis M, Scott J, Frangou S. Impulsivity, personality and bipolar disorder. Eur Psychiatry 2020; 24:464-9. [DOI: 10.1016/j.eurpsy.2009.03.004] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2007] [Revised: 02/15/2009] [Accepted: 03/23/2009] [Indexed: 11/28/2022] Open
Abstract
AbstractBackgroundIncreased impulsivity is a diagnostic feature of mania in bipolar disorder (BD). However it is unclear whether increased impulsivity is also a trait feature of BD and therefore present in remission. Trait impulsivity can also be construed as a personality dimension but the relationship between personality and impulsivity in BD has not been explored. The aim of this study was to examine the relationship of impulsivity to clinical status and personality characteristics in patients with BD.MethodsWe measured impulsivity using the Barratt Impulsiveness Scale (BIS-11) and personality dimensions using Eysenck Personality Questionnaire in 106 BD patients and demographically matched healthy volunteers. Clinical symptoms were assessed in all participants using the Clinical Global Impressions Scale, the Montgomery-Asberg Depression Rating Scale and the Young Mania Rating Scale. Based on their clinical status patients were divided in remitted (n = 36), subsyndromal (n = 25) and syndromal (n = 45).ResultsThere was no difference in BIS-11 and EPQ scores between remitted patients and healthy subjects. Impulsivity, Neuroticism and Psychoticism scores were increased in subsyndromal and syndromal patients. Within the BD group, total BIS-11 score was predicted mainly by symptoms severity followed by Psychoticism and Neuroticism scores.ConclusionsIncreased impulsivity may not be a trait feature of BD. Symptom severity is the most significant determinant of impulsivity measures even in subsyndromal patients.
Collapse
|
44
|
Loftus J, Scott J, Vorspan F, Icick R, Henry C, Gard S, Kahn JP, Leboyer M, Bellivier F, Etain B. Psychiatric comorbidities in bipolar disorders: An examination of the prevalence and chronology of onset according to sex and bipolar subtype. J Affect Disord 2020; 267:258-263. [PMID: 32217226 DOI: 10.1016/j.jad.2020.02.035] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2019] [Revised: 02/05/2020] [Accepted: 02/18/2020] [Indexed: 12/20/2022]
Abstract
OBJECTIVES Bipolar Disorder (BD) is frequently comorbid with other psychiatric disorders. However, few studies systematically examine which disorders are more likely to occur pre- or post-BD onset. We examine the prevalence and Age At Onset (AAO) of psychiatric conditions in adults with BD. METHODS A structured clinical interview was used to assess lifetime history and AAO of alcohol and cannabis misuse, suicide attempts, anxiety and eating disorders in a French sample of euthymic patients with BD (n = 739). Regression analyses were used to test for statistically significant associations between rates and AAO of comorbidities in BD groups stratified by sex or subtype. RESULTS Prevalence of alcohol and cannabis misuse was associated with male sex and BD-I subtype; whilst most anxiety and eating disorders were associated with female sex. The AAO of most comorbid conditions preceded that of BD, except for panic disorder, agoraphobia and alcohol misuse. Few variations were observed in AAO of comorbidities according to groups. LIMITATIONS All assessments were retrospective, so estimates of prevalence rates and especially exact AAO of some comorbidities are at risk of recall bias. CONCLUSIONS Sex and BD subtype are associated with different rates of comorbid disorders. However, there were minimal between group differences in median AAO of comorbidities. By describing the chronological sequence of comorbidities in BD we were able to demonstrate that a minority of comorbidities typically occurred post-onset of BD. This is noteworthy as these disorders might be amenable to interventions aimed at early secondary prevention.
Collapse
|
45
|
Heggelund J, Vancampfort D, Tacchi MJ, Morken G, Scott J. Is there an association between cardiorespiratory fitness and stage of illness in psychotic disorders? A systematic review and meta-analysis. Acta Psychiatr Scand 2020; 141:190-205. [PMID: 31646608 DOI: 10.1111/acps.13119] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/21/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Clinical staging models describe where an individual exists on a continuum from asymptomatic at-risk states (Stage 0) through to established late-stage disease (Stage 4). We applied this framework to systematically assess evidence for any associations between objectively assessed cardiorespiratory fitness (CRF) and stage of psychosis. METHOD Nine electronic databases were searched for relevant publications from inception until October 31, 2019. Pooled effect sizes (Hedges' g and 95% confidence intervals (95% CI)) were estimated for differences in CRF for studies that reported mean oxygen uptake (max, peak, or predicted VO2 in ml/kg/min). RESULTS Thirty-eight studies were eligible. Findings indicated that suboptimal CRF can be present at Stages 0 and 1. Meta-analyses of 22 studies demonstrated that CRF was significantly reduced in individuals classified between Stages 1 and 4 compared with matched or general population controls (g = -0.93; 95% CI -1.14, -0.71). Mean VO2 was decreased by 28% in Stage 4 compared with Stage 1 (34.1 vs. 24.66 ml/kg/min); the largest effect size for CRF reduction was reported between Stages 2 and 3 (g = -1.16; 95% CI -1.31, -1.03). CONCLUSIONS Although not identifying direct causal links between clinical stage and CRF, using this framework may enhance understanding of co-associations between mental and physical health markers across the entire spectrum of psychosis. Limitations include lack of research on CRF in Stages 0 and 1 alongside problems determining stage in some studies. However, impaired CRF is reported in emerging psychosis, supporting calls that early intervention programmes should address both mental and physical wellbeing.
Collapse
|
46
|
Li Q, Kresge C, Boggs K, Scott J, Feranchak A. Mechanosensor transient receptor potential vanilloid member 4 (TRPV4) regulates mouse cholangiocyte secretion and bile formation. Am J Physiol Gastrointest Liver Physiol 2020; 318:G277-G287. [PMID: 31760763 PMCID: PMC7052575 DOI: 10.1152/ajpgi.00176.2019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Mechanosensitive signaling has emerged as a mechanism for the regulation of cholangiocyte transport and bile formation. The mechanical effect of fluid-flow, or shear, at the apical membrane of cholangiocytes regulates secretion through a process involving increases in [Ca2+]i and activation of Ca2+-activated Cl- channels. However, the initiating steps translating shear force to increases in intracellular calcium concentration ([Ca2+]i) are unknown. Transient receptor potential vanilloid member 4 (TRPV4), a nonselective cation channel present in the apical membrane of cholangiocytes, has been proposed as a potential mechanosensor. The aim of the present studies was to determine the potential role of TRPV4 in initiating mechanosensitive signaling in response to fluid-flow in cholangiocytes. TRPV4 expression was confirmed in both small and large mouse cholangiocytes. Exposure of cells to either fluid flow or specific TRPV4 pharmacological agonists rapidly increased both [Ca2+]i and membrane cation currents. Both flow- and agonist-stimulated currents displayed identical biophysical properties and were inhibited in the presence of TRPV4 antagonists or in cells after transfection with TRPV4 small interfering RNA. Transfection of mouse cholangiocytes with a TRPV4-enhanced green fluorescent protein construct increased the expression of TRPV4 and the magnitude of flow-stimulated currents. A specific TRPV4 agonist significantly increased the biliary concentration of ATP and bile flow in live mice when administered intravenously and increased ATP release from cholangiocyte monolayers when applied exogenously. The findings are consistent with a model in which activation of cholangiocyte TRPV4 translates shear force into an acute rise in membrane cation permeability, [Ca2+]i, ATP release, and bile flow. Understanding the role of mechanosensitive transport pathways may provide novel insights to modulate bile flow for the treatment of cholestatic liver disorders.NEW & NOTEWORTHY These studies functionally characterize TRPV4 as a mechanosensitive channel in mouse cholangiocytes. By mediating a rapid rise in intracellular Ca2+, necessary for Ca2+-dependent secretion, TRPV4 represents a mechanosensor responsible for translating fluid flow into intracellular signaling and biliary secretion. Furthermore, intravenous infusion of a specific TRPV4 agonist increases bile flow in live mice. Understanding the role of TRPV4 in mechanosensitive transport pathways may provide novel insights to modulate bile flow during cholestasis.
Collapse
|
47
|
Harris L, Humber J, Agin J, Black J, Boling R, Calicchia M, Cooper C, Dickinson S, Heisick J, Kelly M, Knight M, LaClair D, Marshall C, Newman S, Presla L, Romine A, Schulke M, Scott J, Scott T, Sivey C, Tardio J, Twohy C, Vorhies I, Wagner T, Wazenski T. AutoMicrobic System for Biochemical Identification of Listeria Species Isolated From Foods: Collaborative Study. J AOAC Int 2020. [DOI: 10.1093/jaoac/76.4.822] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
A collaborative study was conducted to evaluate the performance of the AutoMicrobic System Gram- Positive Identification (GPI) and Gram-Negative Identification (GNI) test kits to biochemically characterize Listeria spp. Thirteen laboratories each tested 97 food and environmental isolates, representing the 7 species of Listeria, as well as 11 additional genera of Gram-positive rods. Each collaborator inoculated both a GPI and a GNI card with a pure culture of each organism. The AutoMicrobic System identified the isolates and printed out the biochemical results. The GPI card is used to obtain a species identification and a mannitol reaction result, and the GNI card is used to obtain rhamnose and xylose reaction results. Organisms are classified into species groups and can be further distinguished on the basis of hemolysis or nitrate reduction tests. The AutoMicrobic System method correctly classified 90.8% of the Listeria spp. isolates and 100% of the non-Listeria isolates. The AutoMicrobic System method was adopted first action by AOAC International for the biochemical characterization of Listeria spp. isolated from food and environmental sources.
Collapse
|
48
|
Abbott BP, Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Akutsu T, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Ando M, Angelova SV, Antier S, Appert S, Arai K, Arai K, Arai Y, Araki S, Araya A, Araya MC, Areeda JS, Arène M, Aritomi N, Arnaud N, Arun KG, Ascenzi S, Ashton G, Aso Y, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae SW, Bae YB, Baiotti L, Bajpai R, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bidler J, Bilenko IA, Bilgili SA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DA, Brown DD, Brunett S, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callister TA, Calloni E, Camp JB, Campbell WA, Canepa M, Cannon K, Cannon KC, Cao H, Cao J, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Diaz JC, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chakravarti K, Chamberlin SJ, Chan M, Chan ML, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Cheeseboro BD, Chen CS, Chen HY, Chen KH, Chen X, Chen Y, Chen YR, Cheng HP, Cheong CK, Chia HY, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu HY, Chu Q, Chu YK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colgan R, Colleoni M, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D’Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Datrier LEH, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Pozzo WD, DeMarchi LM, Demos N, Dent T, De Pietri R, Derby J, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Fiore LD, Giovanni MD, Girolamo TD, Lieto AD, Ding B, Pace SD, Palma ID, Renzo FD, Dmitriev A, Doctor Z, Doi K, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eguchi S, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Enomoto Y, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Fee C, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Flynn E, Fong H, Font JA, Forsyth PWF, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fujii Y, Fukunaga M, Fukushima M, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Ge GG, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Godwin P, Goetz E, Goetz R, Goncharov B, González G, Castro JMG, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo Y, Gupta A, Gupta MK, Gustafson EK, Gustafson R, Haegel L, Hagiwara A, Haino S, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hasegawa K, Haster CJ, Haughian K, Hayakawa H, Hayama K, Hayes FJ, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Himemoto Y, Hinderer T, Hiranuma Y, Hirata N, Hirose E, Hoak D, Hochheim S, Hofman D, Holgado AM, Holland NA, Holt K, Holz DE, Hong Z, Hopkins P, Horst C, Hough J, Howell EJ, Hoy CG, Hreibi A, Hsieh BH, Huang GZ, Huang PW, Huang YJ, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Idzkowski B, Iess A, Ikenoue B, Imam S, Inayoshi K, Ingram C, Inoue Y, Inta R, Intini G, Ioka K, Irwin B, Isa HN, Isac JM, Isi M, Itoh Y, Iyer BR, Izumi K, Jacqmin T, Jadhav SJ, Jani K, Janthalur NN, Jaranowski P, Jenkins AC, Jiang J, Johnson DS, Jones AW, Jones DI, Jones R, Jonker RJG, Ju L, Jung K, Jung P, Junker J, Kajita T, Kalaghatgi CV, Kalogera V, Kamai B, Kamiizumi M, Kanda N, Kandhasamy S, Kang GW, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kashyap R, Kasprzack M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kawaguchi K, Kawai N, Kawasaki T, Keerthana NV, Kéfélian F, Keitel D, Kennedy R, Key JS, Khalili FY, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Khursheed M, Kijbunchoo N, Kim C, Kim C, Kim JC, Kim J, Kim K, Kim W, Kim WS, Kim YM, Kimball C, Kimura N, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kita N, Kitazawa H, Kleybolte L, Klika JH, Klimenko S, Knowles TD, Knyazev E, Koch P, Koehlenbeck SM, Koekoek G, Kojima Y, Kokeyama K, Koley S, Komori K, Kondrashov V, Kong AKH, Kontos A, Koper N, Korobko M, Korth WZ, Kotake K, Kowalska I, Kozak DB, Kozakai C, Kozu R, Kringel V, Krishnendu N, Królak A, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar R, Kumar S, Kume J, Kuo CM, Kuo HS, Kuo L, Kuroyanagi S, Kusayanagi K, Kutynia A, Kwak K, Kwang S, Lackey BD, Lai KH, Lam TL, Landry M, Lane BB, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee CH, Lee HK, Lee HM, Lee HW, Lee J, Lee K, Lee RK, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li KJL, Li TGF, Li X, Lin CY, Lin F, Lin FL, Lin LCC, Linde F, Linker SD, Littenberg TB, Liu GC, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lower ME, Lück H, Lumaca D, Lundgren AP, Luo LW, Lynch R, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod DM, Macquet A, Magaña-Sandoval F, Zertuche LM, Magee RM, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marchio M, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Mehta AK, Meidam J, Melatos A, Mendell G, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Michimura Y, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Millhouse M, Mills JC, Milovich-Goff MC, Minazzoli O, Minenkov Y, Mio N, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Miyamoto A, Miyazaki Y, Miyo K, Miyoki S, Mo G, Moffa D, Mogushi K, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Moriwaki Y, Mours B, Mow-Lowry CM, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagano K, Nagano S, Nagar A, Nakamura K, Nakano H, Nakano M, Nakashima R, Nardecchia I, Narikawa T, Naticchioni L, Nayak RK, Negishi R, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Ng KY, Ng S, Nguyen P, Ni WT, Nichols D, Nishizawa A, Nissanke S, Nocera F, North C, Nuttall LK, Obergaulinger M, Oberling J, O’Brien BD, Obuchi Y, O’Dea GD, Ogaki W, Ogin GH, Oh JJ, Oh SH, Ohashi M, Ohishi N, Ohkawa M, Ohme F, Ohta H, Okada MA, Okutomi K, Oliver M, Oohara K, Ooi CP, Oppermann P, Oram RJ, O’Reilly B, Ormiston RG, Ortega LF, O’Shaughnessy R, Oshino S, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan HW, Pan KC, Pang B, Pang HF, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Park J, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pele A, Arellano FEP, Penn S, Perez CJ, Perreca A, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pillant G, Pinard L, Pinto I, Pirello M, Pitkin M, Poggiani R, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Powell J, Prajapati AK, Prasad J, Prasai K, Prasanna R, Pratten G, Prestegard T, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez PJ, Quintero EA, Quitzow-James R, Raab FJ, Radkins H, Radulescu N, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Richardson CJ, Richardson JW, Ricker PM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romanelli M, Romano R, Romel CL, Romie JH, Rose K, Rosińska D, Rosofsky SG, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sago N, Saito S, Saito Y, Sakai K, Sakai Y, Sakamoto H, Sakellariadou M, Sakuno Y, Salconi L, Saleem M, Samajdar A, Sammut L, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Santiago KA, Sarin N, Sassolas B, Sathyaprakash BS, Sato S, Sato T, Sauter O, Savage RL, Sawada T, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sekiguchi T, Sekiguchi Y, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Shahriar MS, Shaner MB, Shao L, Sharma P, Shawhan P, Shen H, Shibagaki S, Shimizu R, Shimoda T, Shimode K, Shink R, Shinkai H, Shishido T, Shoda A, Shoemaker DH, Shoemaker DM, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh N, Singhal A, Sintes AM, Sitmukhambetov S, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smith JR, Smith RJE, Somala S, Somiya K, Son EJ, Sorazu B, Sorrentino F, Sotani H, Souradeep T, Sowell E, Spencer AP, Srivastava AK, Srivastava V, Staats K, Stachie C, Standke M, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Sudhir V, Sugimoto R, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Suzuki T, Suzuki T, Swinkels BL, Szczepańczyk MJ, Tacca M, Tagoshi H, Tait SC, Takahashi H, Takahashi R, Takamori A, Takano S, Takeda H, Takeda M, Talbot C, Talukder D, Tanaka H, Tanaka K, Tanaka K, Tanaka T, Tanaka T, Tanioka S, Tanner DB, Tápai M, Martin ENTS, Taracchini A, Tasson JD, Taylor R, Telada S, Thies F, Thomas M, Thomas P, Thondapu SR, Thorne KA, Thrane E, Tiwari S, Tiwari S, Tiwari V, Toland K, Tomaru T, Tomigami Y, Tomura T, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Tringali MC, Trovato A, Trozzo L, Trudeau R, Tsang KW, Tsang TTL, Tse M, Tso R, Tsubono K, Tsuchida S, Tsukada L, Tsuna D, Tsuzuki T, Tuyenbayev D, Uchikata N, Uchiyama T, Ueda A, Uehara T, Ueno K, Ueshima G, Ugolini D, Unnikrishnan CS, Uraguchi F, Urban AL, Ushiba T, Usman SA, Vahlbruch H, Vajente G, Valdes G, Bakel NV, Beuzekom MV, Brand JFJVD, Broeck CVD, Vander-Hyde DC, Schaaf LVD, Heijningen JVV, Putten MHPMV, Veggel AAV, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vine DJ, Vinet JY, Vitale S, Vivanco FH, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang J, Wang JZ, Wang WH, Wang YF, Ward RL, Warden ZA, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westhouse JW, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken DM, Williams D, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Worden J, Wright JL, Wu CM, Wu DS, Wu HC, Wu SR, Wysocki DM, Xiao L, Xu WR, Yamada T, Yamamoto H, Yamamoto K, Yamamoto K, Yamamoto T, Yancey CC, Yang L, Yap MJ, Yazback M, Yeeles DW, Yokogawa K, Yokoyama J, Yokozawa T, Yoshioka T, Yu H, Yu H, Yuen SHR, Yuzurihara H, Yvert M, Zadrożny AK, Zanolin M, Zeidler S, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhao Y, Zhou M, Zhou Z, Zhu XJ, Zhu ZH, Zimmerman AB, Zucker ME, Zweizig J. Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. LIVING REVIEWS IN RELATIVITY 2020; 23:3. [PMID: 33015351 PMCID: PMC7520625 DOI: 10.1007/s41114-020-00026-9] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 05/27/2020] [Indexed: 05/05/2023]
Abstract
We present our current best estimate of the plausible observing scenarios for the Advanced LIGO, Advanced Virgo and KAGRA gravitational-wave detectors over the next several years, with the intention of providing information to facilitate planning for multi-messenger astronomy with gravitational waves. We estimate the sensitivity of the network to transient gravitational-wave signals for the third (O3), fourth (O4) and fifth observing (O5) runs, including the planned upgrades of the Advanced LIGO and Advanced Virgo detectors. We study the capability of the network to determine the sky location of the source for gravitational-wave signals from the inspiral of binary systems of compact objects, that is binary neutron star, neutron star-black hole, and binary black hole systems. The ability to localize the sources is given as a sky-area probability, luminosity distance, and comoving volume. The median sky localization area (90% credible region) is expected to be a few hundreds of square degrees for all types of binary systems during O3 with the Advanced LIGO and Virgo (HLV) network. The median sky localization area will improve to a few tens of square degrees during O4 with the Advanced LIGO, Virgo, and KAGRA (HLVK) network. During O3, the median localization volume (90% credible region) is expected to be on the order of 10 5 , 10 6 , 10 7 Mpc 3 for binary neutron star, neutron star-black hole, and binary black hole systems, respectively. The localization volume in O4 is expected to be about a factor two smaller than in O3. We predict a detection count of 1 - 1 + 12 ( 10 - 10 + 52 ) for binary neutron star mergers, of 0 - 0 + 19 ( 1 - 1 + 91 ) for neutron star-black hole mergers, and 17 - 11 + 22 ( 79 - 44 + 89 ) for binary black hole mergers in a one-calendar-year observing run of the HLV network during O3 (HLVK network during O4). We evaluate sensitivity and localization expectations for unmodeled signal searches, including the search for intermediate mass black hole binary mergers.
Collapse
|
49
|
Kjørstad K, Sivertsen B, Langsrud K, Vedaa Ø, Vethe D, Faaland P, Vestergaard C, Scott J, Kallestad H. Will treatment of insomnia also reduce work-related impairment? Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Abbott BP, Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Ascenzi S, Ashton G, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baird J, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Bals A, Banagiri S, Barayoga JC, Barbieri C, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Benjamin MG, Berger BK, Bergmann G, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bidler J, Biggs E, Bilenko IA, Bilgili SA, Billingsley G, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bobba F, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose S, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Breschi M, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Campbell WA, Cannon KC, Cao H, Cao J, Carapella G, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi O, Chakravarti K, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Cheong CK, Chia HY, Chiadini F, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu Q, Chua S, Chung KW, Chung S, Ciani G, Cieślar M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Coccia E, Cohadon PF, Cohen D, Colleoni M, Collette CG, Collins C, Colpi M, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, D'Angelo B, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Datrier LEH, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, DeMarchi LM, Demos N, Dent T, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, DiFronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla AK, Dmitriev A, Doctor Z, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Durante O, Dwyer SE, Easter PJ, Eddolls G, Edo TB, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Errico L, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Fee C, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fittipaldi R, Fitz-Axen M, Fiumara V, Flaminio R, Fletcher M, Floden E, Flynn E, Fong H, Font JA, Forsyth PWF, Fournier JD, Vivanco FH, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fronzè G, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Gaonkar SG, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Gibson DR, Gill K, Glover L, Gniesmer J, Godwin P, Goetz E, Goetz R, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gossan SE, Gosselin M, Gouaty R, Grace B, Grado A, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson EM, Grimaldi A, Grimm SJ, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo Y, Gupta A, Gupta A, Gupta P, Gustafson EK, Gustafson R, Haegel L, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hansen TJ, Hanson J, Harder T, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hasskew RK, Haster CJ, Haughian K, Hayes FJ, Healy J, Heidmann A, Heintze MC, Heitmann H, Hellman F, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heurs M, Hild S, Hinderer T, Hochheim S, Hofman D, Holgado AM, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Howell EJ, Hoy CG, Huang Y, Hübner MT, Huerta EA, Huet D, Hughey B, Hui V, Husa S, Huttner SH, Huynh-Dinh T, Idzkowski B, Iess A, Inchauspe H, Ingram C, Inta R, Intini G, Irwin B, Isa HN, Isac JM, Isi M, Iyer BR, Jacqmin T, Jadhav SJ, Jani K, Janthalur NN, Jaranowski P, Jariwala D, Jenkins AC, Jiang J, Johnson DS, Jones AW, Jones DI, Jones JD, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Kashyap R, Kasprzack M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana NV, Kéfélian F, Keitel D, Kennedy R, Key JS, Khalili FY, Khan I, Khan S, Khazanov EA, Khetan N, Khursheed M, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimball C, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klika JH, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koekoek G, Koley S, Kondrashov V, Kontos A, Koper N, Korobko M, Korth WZ, Kovalam M, Kozak DB, Krämer C, Kringel V, Krishnendu N, Królak A, Krupinski N, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar R, Kuo L, Kutynia A, Kwang S, Lackey BD, Laghi D, Lai KH, Lam TL, Landry M, Lane BB, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee CH, Lee HK, Lee HM, Lee HW, Lee J, Lee K, Lehmann J, Lenon AK, Leroy N, Letendre N, Levin Y, Li A, Li J, Li KJL, Li TGF, Li X, Lin F, Linde F, Linker SD, Littenberg TB, Liu J, Liu X, Llorens-Monteagudo M, Lo RKL, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lower ME, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod DM, Macquet A, Magaña Hernandez I, Magaña-Sandoval F, Magee RM, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Mapelli M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martinez V, Martynov DV, Masalehdan H, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, McCann JJ, McCarthy R, McClelland DE, McClincy P, McCormick S, McCuller L, McGuire SC, McIsaac C, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Mehta AK, Meidam J, Mejuto Villa E, Melatos A, Mendell G, Mercer RA, Mereni L, Merfeld K, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Messina F, Metzdorff R, Meyers PM, Meylahn F, Miani A, Miao H, Michel C, Middleton H, Milano L, Miller AL, Millhouse M, Mills JC, Milovich-Goff MC, Minazzoli O, Minenkov Y, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Mo G, Moffa D, Mogushi K, Mohapatra SRP, Molina-Ruiz M, Mondin M, Montani M, Moore CJ, Moraru D, Morawski F, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Muciaccia F, Mukherjee A, Mukherjee D, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nardecchia I, Naticchioni L, Nayak RK, Neil BF, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Ng KY, Ng S, Nguyen C, Nguyen P, Nichols D, Nichols SA, Nissanke S, Nocera F, North C, Nuttall LK, Obergaulinger M, Oberling J, O'Brien BD, Oganesyan G, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston RG, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page MA, Pagliaroli G, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pan H, Panda PK, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Payne E, Pearlstone BL, Pechsiri TC, Pedersen AJ, Pedraza M, Pedurand R, Pele A, Penn S, Perego A, Perez CJ, Périgois C, Perreca A, Petermann J, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Plastino W, Poggiani R, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Powell J, Prajapati AK, Prasad J, Prasai K, Prasanna R, Pratten G, Prestegard T, Principe M, Prodi GA, Prokhorov L, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez PJ, Raab FJ, Raaijmakers G, Radkins H, Radulesco N, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Rettegno P, Ricci F, Richardson CJ, Richardson JW, Ricker PM, Riemenschneider G, Riles K, Rizzo M, Robertson NA, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romanelli M, Romano R, Romel CL, Romie JH, Rose CA, Rose D, Rose K, Rosińska D, Rosofsky SG, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salafia OS, Salconi L, Saleem M, Samajdar A, Sammut L, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sanders JR, Santiago KA, Santos E, Sarin N, Sassolas B, Sathyaprakash BS, Sauter O, Savage RL, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schulte BW, Schutz BF, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Shahriar MS, Shaner MB, Sharma A, Sharma P, Shawhan P, Shen H, Shink R, Shoemaker DH, Shoemaker DM, Shukla K, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Singer LP, Singh D, Singh N, Singhal A, Sintes AM, Sitmukhambetov S, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smith JR, Smith RJE, Somala S, Son EJ, Soni S, Sorazu B, Sorrentino F, Souradeep T, Sowell E, Spencer AP, Spera M, Srivastava AK, Srivastava V, Staats K, Stachie C, Standke M, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Sudhir V, Summerscales TZ, Sun L, Sunil S, Sur A, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Tanner DB, Tao D, Tápai M, Tapia A, Tasson JD, Taylor R, Tenorio R, Terkowski L, Thomas M, Thomas P, Thondapu SR, Thorne KA, Thrane E, Tiwari S, Tiwari S, Tiwari V, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Tringali MC, Tripathee A, Trovato A, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tsutsui T, Tuyenbayev D, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Valentini M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, VanHeijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang H, Wang JZ, Wang S, Wang WH, Wang YF, Ward RL, Warden ZA, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westhouse JW, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken DM, Williams D, Williamson AR, Willis JL, Willke B, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wright JL, Wu DS, Wysocki DM, Xiao S, Xu R, Yamamoto H, Yancey CC, Yang L, Yang Y, Yang Z, Yap MJ, Yazback M, Yeeles DW, Yu H, Yu H, Yuen SHR, Zadrożny AK, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhao G, Zhou M, Zhou Z, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J, Shandera S. Search for Subsolar Mass Ultracompact Binaries in Advanced LIGO's Second Observing Run. PHYSICAL REVIEW LETTERS 2019; 123:161102. [PMID: 31702344 DOI: 10.1103/physrevlett.123.161102] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2019] [Indexed: 06/10/2023]
Abstract
We present a search for subsolar mass ultracompact objects in data obtained during Advanced LIGO's second observing run. In contrast to a previous search of Advanced LIGO data from the first observing run, this search includes the effects of component spin on the gravitational waveform. We identify no viable gravitational-wave candidates consistent with subsolar mass ultracompact binaries with at least one component between 0.2 M_{⊙}-1.0 M_{⊙}. We use the null result to constrain the binary merger rate of (0.2 M_{⊙}, 0.2 M_{⊙}) binaries to be less than 3.7×10^{5} Gpc^{-3} yr^{-1} and the binary merger rate of (1.0 M_{⊙}, 1.0 M_{⊙}) binaries to be less than 5.2×10^{3} Gpc^{-3} yr^{-1}. Subsolar mass ultracompact objects are not expected to form via known stellar evolution channels, though it has been suggested that primordial density fluctuations or particle dark matter with cooling mechanisms and/or nuclear interactions could form black holes with subsolar masses. Assuming a particular primordial black hole (PBH) formation model, we constrain a population of merging 0.2 M_{⊙} black holes to account for less than 16% of the dark matter density and a population of merging 1.0 M_{⊙} black holes to account for less than 2% of the dark matter density. We discuss how constraints on the merger rate and dark matter fraction may be extended to arbitrary black hole population models that predict subsolar mass binaries.
Collapse
|